Within each cohort, there was a nonsignificant trend toward increased response rate for tumors with CPS ≥1 [54.9% (95% CI, 43.5–65.9; 45/82) for dMMR/MSI-H EC, and 21.7% (95% CI, 12.1–34.2; 13/60) for MMRp/MSS EC, Table 2 ].
← all excerpts
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
1
—
—